Project Grant R44NS145814
Award Date 8/27/25
Completion Date 7/31/27
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
KNG OF PRUSSA, PA 19406, USA
Similar Awards
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $699,559 to Merlin Therapeutics Inc. to develop a novel adeno-associated viral vector 9 (AAV9) gene therapy for the treatment of neurofibromatosis type 2 (NF2). The therapy aims to express a healthy copy of the NF2 gene and rescue tumor characteristics in NF2...
- This federal Project Grant award for $699,818 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is supporting the development of a novel adeno-associated virus (AAV) gene therapy product for treating the central nervous system neuropathy associated with Mucopolysaccharidosis Type IIIC (MPS IIIC), a rare lysosomal storage disease currently lacking effective treatments. The...
- This $1,151,209 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at The Leland Stanford Junior University to investigate a novel molecular driver of schwannoma nerve sheath tumors. The researchers discovered recurrent mutations in the SOX10 gene in a subset of sporadic schwannomas and hypothesize these alterations drive tumor...
- This Project Grant award of $500,000, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a gene therapy for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD). The project aims to develop a blood-brain barrier penetrable adeno-associated virus (AAV) vector containing a functional copy of the human...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $190,485 to Indiana University Indianapolis to investigate the molecular mechanisms of differentiation failure in NF2 mutant neuroepithelial stem cells. The 5-year project aims to identify the cellular hierarchy in NF2-deficient stem cells, define dysregulated signaling pathways,...
- This $1,009,212 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant is funding research by the Van Andel Research Institute (VAI) to develop a novel gene therapy approach to reduce neurotoxicity in Parkinson's disease. Key activities include conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to...
- This $420,251 Project Grant awarded on May 6, 2025 by the National Institute of Neurological Disorders and Stroke (CFDA 93.853) supports research on the development of encapsulated cell-based oncolytic virus therapy for glioblastoma (GBM), the most lethal primary brain tumor. The award recipient, Brigham & Women's Hospital Inc., will utilize mesenchymal stem cells (MSCs) engineered to express oncolytic herpes simplex virus (OHSV) variants in combination with immune-modulators like...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $722,587 to Neurogt Inc., a minority-owned, woman-owned small business, to further develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis (MPS) I, a rare lysosomal storage disease. The goal is to advance this gene replacement therapy toward clinical application and commercialization. The project builds on previous...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $500,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Renerva LLC, a for-profit biomedical company based in Pittsburgh, PA. The grant, titled "PNM-CAP: A Novel Nerve Cap to Prevent Painful Neuroma Formation in Peripheral Nerve Injuries and Amputations", will support the development of a biodegradable nerve capping device to prevent the formation of painful neuromas...
- This federal Project Grant award of $564,045 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to develop novel small molecules for epigenetic therapy of medulloblastoma, the most common and aggressive malignant brain tumor in children. The key objectives are to perform medicinal chemistry to optimize a promising chemical scaffold and conduct further preclinical...